Department of Pediatric Allergy and Immunology, Kanuni Sultan Suleyman Training, and Research Hospital, Istanbul, Turkey.
Department of Pediatric Pulmonology, Kanuni Sultan Suleyman Training, and Research Hospital, Istanbul, Turkey.
Ann Allergy Asthma Immunol. 2021 May;126(5):569-575. doi: 10.1016/j.anai.2021.01.018. Epub 2021 Jan 23.
Coronavirus disease 2019 (COVID-19) emerged as a pandemic toward the end of 2019, causing large numbers of people to become infected and die.
To determine whether allergic diseases are a risk factor for hospitalization in COVID-19.
We conducted a study including 107 pediatric patients after COVID-19 recovery. The International Study of Asthma and Allergies in Childhood Phase 3 questionnaires were distributed together with a detailed history of environmental factors and an allergic evaluation including skin prick tests, specific immunoglobulin E tests, and spirometry. We investigated the prevalence of allergic diseases and evaluated the factors associated with hospitalization in COVID-19.
A total of 61 (57%) patients were hospitalized and 46 (43%) patients were followed closely in the outpatient clinic. The prevalences of allergic rhinitis, asthma, atopic dermatitis, and episodic wheezing were 10.3%, 6,5%, 4.7%, and 3.7%, respectively, within the whole study population. Although having asthma with or without allergic rhinitis, atopic dermatitis, and passive tobacco exposure were not found to be related to hospitalization because of COVID-19, having a pet at home was found to decrease the risk of hospitalization (odds ratio, 0.191; 95% confidence interval, 0.047-0.779; P = .02). Spirometry tests revealed a higher forced expiratory volume in one second to forced vital capacity ratio and a peak expiratory flow reversibility in hospitalized patients than in nonhospitalized ones (P = .02 and P = .003, respectively).
Asthma and allergic diseases do not seem to be risk factors for hospitalization in children because of COVID-19, and having a pet at home can be a protective effect. Pulmonary function testing seems to be important for monitoring lung damage after COVID-19.
2019 年底,冠状病毒病 2019(COVID-19)爆发成为大流行,导致大量人员感染和死亡。
确定过敏性疾病是否是 COVID-19 住院的危险因素。
我们进行了一项研究,包括 107 名 COVID-19 康复后的儿科患者。我们发放了《国际儿童哮喘和过敏研究》第 3 阶段问卷,并详细询问了环境因素和过敏评估史,包括皮肤点刺试验、特异性免疫球蛋白 E 检测和肺功能检查。我们调查了过敏性疾病的患病率,并评估了与 COVID-19 住院相关的因素。
共有 61 名(57%)患者住院,46 名(43%)患者在门诊密切随访。在整个研究人群中,过敏性鼻炎、哮喘、特应性皮炎和间歇性喘息的患病率分别为 10.3%、6.5%、4.7%和 3.7%。尽管患有哮喘伴或不伴过敏性鼻炎、特应性皮炎和被动吸烟与 COVID-19 住院无关,但家中有宠物被发现可降低住院风险(比值比,0.191;95%置信区间,0.047-0.779;P =.02)。与非住院患者相比,住院患者的用力呼气量一秒率和呼气峰流速可逆性更高(P =.02 和 P =.003)。
哮喘和过敏性疾病似乎不是 COVID-19 儿童住院的危险因素,家中有宠物可能具有保护作用。肺功能检查对于监测 COVID-19 后肺损伤似乎很重要。